发明名称 Compositions for treatment of attention deficit hyperactivity disorder
摘要 Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
申请公布号 US9283214(B2) 申请公布日期 2016.03.15
申请号 US201514704836 申请日期 2015.05.05
申请人 Ironshore Pharmaceuticals & Development, Inc. 发明人 Lickrish David;Zhang Feng
分类号 A61K31/4458;A61K9/48;A61K9/50 主分类号 A61K31/4458
代理机构 Vinson & Elkins LLP 代理人 Vinson & Elkins LLP
主权项 1. A solid, oral pharmaceutical composition comprising: a single population of beads, said beads comprising:a core comprising methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient; a sustained release layer enclosing the core; and a delayed release layer enclosing the sustained release layer, wherein when the formulation is administered to a human subject in a fasted state, (i) there is a lag of at least 7 hours during which the plasma concentration of methylphenidate is less than 5% of the maximum plasma (Cmax), (ii) a plasma area under the curve at 10 hours (AUC0-10) after administration that is less than about 7% of AUC0-48; and (iii) wherein the time to Cmax (Tmax) is between 12 and 19 hours after administration, and wherein administration to a population of subjects provides a significant improvement in ADHD related behavior or cognitive ability over a period of at least 12 continuous hours as measured by a validated rating scale.
地址 Camana Bay KY